Login to Your Account



Other News To Note


Friday, July 26, 2013

• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said an article published in PLOS One, based on a study conducted at the Moffitt Cancer Center examining the immunologic mechanism of PV-10 in murine models of breast cancer and melanoma, concluded intralesional administration of the drug reduced the growth of directly injected tumors and led to the induction of a robust antitumor T-cell response.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription